Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.
第一作者:
Nirosen,Vijiaratnam
第一单位:
Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, University College London, London, UK.
作者:
医学主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);女(雌)性(Female);人类(Humans);男(雄)性(Male);中年人(Middle Aged);疾病恶化(Disease Progression);双盲法(Double-Blind Method);用药计划表(Drug Administration Schedule);帕金森病(Parkinson Disease);治疗结果(Treatment Outcome)
DOI
10.1016/S0140-6736(24)02808-3
PMID
39919773
发布时间
2025-05-19
- 浏览0
Lancet (London, England)
627-636页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



